Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer.
The number of published studies on peritoneal dissemination of scirrhous gastric carcinoma is very small as a result of the unavailability of highly reproducible animal models. Orthotopic implantation of HSC-44PE and HSC-58 (scirrhous gastric carcinoma-derived cell lines) cells into nude mice led to dissemination of the tumor cells to the greater omentum, mesenterium, peritoneum and so on, and caused ascites in a small number of animals. Cycles of isolation of the ascitic tumor cells and orthotopic inoculation of these cells were repeated in turn to animals. This was to isolate highly metastatic cell lines with a strong capability of inducing the formation of ascites (44As3 from HSC-44PE; 58As1 and 58As9 from HSC-58). All three cell lines induced tumor formation at the site of orthotopic injection, and caused fatal cancerous peritonitis and bloody ascites in 90-100% of the animals approximately 3-5 weeks after the inoculation. When the parent cells were implanted, the animals became moribund in approximately 12-18 weeks, however, none of the animals developed ascites. Complementary DNA microarray and immunohistochemical analyses revealed differences in the expression levels of genes coding for the matrix proteinase, cell adhesion, motility, angiogenesis and proliferation between the highly metastatic- and parent-cell lines. The usefulness of this model for the evaluation of drugs was assessed by analyzing the stability of the metastatic potential of the cells and the reproducibility. Animals intravenously treated with CPT-11 and GEM showed suppressed tumor growth and significantly prolonged survival. The metastatic cell lines and the in vivo model established in the present study are expected to serve as a model of cancerous peritonitis developing from primary lesions, and as a useful means of clarifying the pathophysiology of peritoneal dissemination of scirrhous gastric carcinoma and the development of drugs for its treatment.
Yanagihara
Kazuyoshi
K
Central Animal Laboratory, National Cancer Center Research Institute, Tokyo, Japan. kyanagih@gan2.res.ncc.go.jp
Takigahira
Misato
M
Tanaka
Hiromi
H
Komatsu
Teruo
T
Fukumoto
Hisao
H
Koizumi
Fumiaki
F
Nishio
Kazuto
K
Ochiya
Takahiro
T
Ino
Yoshinori
Y
Hirohashi
Setsuo
S
D002293:Adenocarcinoma, Scirrhous / Q000556:secondary* / Q000662:veterinary*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001201:Ascites; D049109:Cell Proliferation; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic; D020411:Oligonucleotide Array Sequence Analysis; D010534:Peritoneal Neoplasms / Q000556:secondary* / Q000662:veterinary*; D013274:Stomach Neoplasms / Q000473:pathology* / Q000662:veterinary*; D013534:Survival; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents